Surmodics Stock Performance
| SRDX Stock | USD 29.66 0.33 1.10% |
SurModics has a performance score of 3 on a scale of 0 to 100. The entity has a beta of -0.22, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning SurModics are expected to decrease at a much lower rate. During the bear market, SurModics is likely to outperform the market. SurModics right now has a risk of 2.17%. Please validate SurModics total risk alpha, downside variance, as well as the relationship between the Downside Variance and daily balance of power , to decide if SurModics will be following its existing price patterns.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in SurModics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain fundamental indicators, SurModics may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
| Begin Period Cash Flow | 41.4 M |
SurModics | Build AI portfolio with SurModics Stock |
SurModics Relative Risk vs. Return Landscape
If you would invest 2,825 in SurModics on April 9, 2025 and sell it today you would earn a total of 141.00 from holding SurModics or generate 4.99% return on investment over 90 days. SurModics is currently generating 0.1046% in daily expected returns and assumes 2.1657% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than SurModics, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
SurModics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SurModics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SurModics, and traders can use it to determine the average amount a SurModics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0483
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | SRDX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.17 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.1 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average SurModics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SurModics by adding it to a well-diversified portfolio.
SurModics Fundamentals Growth
SurModics Stock prices reflect investors' perceptions of the future prospects and financial health of SurModics, and SurModics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SurModics Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.0144 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 430.49 M | ||||
| Shares Outstanding | 14.3 M | ||||
| Price To Earning | 69.21 X | ||||
| Price To Book | 3.89 X | ||||
| Price To Sales | 3.53 X | ||||
| Revenue | 126.08 M | ||||
| EBITDA | 4.73 M | ||||
| Cash And Equivalents | 22.09 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 33.24 M | ||||
| Debt To Equity | 0.12 % | ||||
| Book Value Per Share | 7.71 X | ||||
| Cash Flow From Operations | 248 K | ||||
| Earnings Per Share | (1.40) X | ||||
| Total Asset | 178.56 M | ||||
| Retained Earnings | 75.71 M | ||||
| Current Asset | 58.56 M | ||||
| Current Liabilities | 10.13 M | ||||
About SurModics Performance
Evaluating SurModics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SurModics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SurModics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Surmodics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 389 people.Things to note about SurModics performance evaluation
Checking the ongoing alerts about SurModics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SurModics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 126.08 M. Net Loss for the year was (11.54 M) with profit before overhead, payroll, taxes, and interest of 90.78 M. | |
| SurModics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors |
- Analyzing SurModics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SurModics' stock is overvalued or undervalued compared to its peers.
- Examining SurModics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SurModics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of SurModics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SurModics' stock. These opinions can provide insight into SurModics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.